IT1254280B - Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson - Google Patents
Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinsonInfo
- Publication number
- IT1254280B IT1254280B ITMI920591A ITMI920591A IT1254280B IT 1254280 B IT1254280 B IT 1254280B IT MI920591 A ITMI920591 A IT MI920591A IT MI920591 A ITMI920591 A IT MI920591A IT 1254280 B IT1254280 B IT 1254280B
- Authority
- IT
- Italy
- Prior art keywords
- treatment
- pharmaceutical compositions
- compositions including
- parkinson disease
- derivatives suitable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invenzione si riferisce a composizioni farmaceutiche comprendenti monosialoganglioside GM1, o un suo derivato scelto fra l'estere interno AGF2 e l'estere metilico AGF4, atte al trattamento della patologia parkinsoniana.Un ulteriore oggetto della presente invenzione è una terapia associata per il trattamento della malattia di Parkinson, rappresentata dalla somministrazione di detti composti e di farmaci noti attivi nel sopraindicato trattamento, ed in modo preferenziale la terapia associata con L-Dopa.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI920591A IT1254280B (it) | 1992-03-13 | 1992-03-13 | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson |
JP5515350A JP2872809B2 (ja) | 1992-03-13 | 1993-03-12 | モノシアロガングリオシドgm▲下1▼またはその誘導体を含有する,パーキンソン病の治療に適する医薬組成物 |
EP96116051A EP0770389B1 (en) | 1992-03-13 | 1993-03-12 | Use of monosialoganglioside GM1 or N-dichloro-acetyl-lyso-GM1 for preventing or reversing neuronal degeneration induced by a long term treatment with L-DOPA in the therapy of Parkinson's disease |
AU37477/93A AU3747793A (en) | 1992-03-13 | 1993-03-12 | Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease |
PCT/EP1993/000571 WO1993017691A2 (en) | 1992-03-13 | 1993-03-12 | Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease |
ES96116051T ES2161953T3 (es) | 1992-03-13 | 1993-03-12 | Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson. |
DE69330842T DE69330842T2 (de) | 1992-03-13 | 1993-03-12 | Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration |
EP93906509A EP0630250A1 (en) | 1992-03-13 | 1993-03-12 | Pharmaceutical compositions containing monosialoganglioside gm 1? or a derivative thereof suitable for the treatment of parkinson's disease |
AT96116051T ATE206053T1 (de) | 1992-03-13 | 1993-03-12 | Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration |
US08/304,391 US6620792B1 (en) | 1992-03-13 | 1994-09-12 | Pharmaceutical compositions containing monosialoganglioside GM1 or derivative thereof suitable for the treatment of parkinson's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI920591A IT1254280B (it) | 1992-03-13 | 1992-03-13 | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson |
Publications (3)
Publication Number | Publication Date |
---|---|
ITMI920591A0 ITMI920591A0 (it) | 1992-03-13 |
ITMI920591A1 ITMI920591A1 (it) | 1993-09-13 |
IT1254280B true IT1254280B (it) | 1995-09-14 |
Family
ID=11362423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ITMI920591A IT1254280B (it) | 1992-03-13 | 1992-03-13 | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson |
Country Status (8)
Country | Link |
---|---|
US (1) | US6620792B1 (it) |
EP (2) | EP0630250A1 (it) |
JP (1) | JP2872809B2 (it) |
AT (1) | ATE206053T1 (it) |
DE (1) | DE69330842T2 (it) |
ES (1) | ES2161953T3 (it) |
IT (1) | IT1254280B (it) |
WO (1) | WO1993017691A2 (it) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1259176B (it) * | 1992-10-23 | 1996-03-11 | Fidia Spa | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso |
JP2005527467A (ja) * | 2001-08-29 | 2005-09-15 | ネオーズ テクノロジーズ, インコーポレイテッド | 新規な合成ガングリオシド誘導体およびその組成物 |
EP1367395A1 (de) | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
US7943750B2 (en) * | 2007-06-18 | 2011-05-17 | Laboratoire Medidom S.A. | Process for obtaining pure monosialoganglioside GM1 for medical use |
CN101732331B (zh) * | 2008-11-20 | 2012-05-23 | 北京四环制药有限公司 | 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物 |
WO2014172372A1 (en) | 2013-04-15 | 2014-10-23 | Northwestern University | Treatment for dopaminergic disorders |
CN104490837A (zh) * | 2014-12-30 | 2015-04-08 | 哈尔滨医科大学科技开发总公司 | 单唾液酸四己糖神经节苷脂钠的口服制剂 |
RU2632710C2 (ru) * | 2016-03-31 | 2017-10-09 | Лонг Шенг Фарма Лимитед | Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе |
CN108815131B (zh) * | 2018-09-11 | 2021-01-01 | 四川奇格曼药业有限公司 | 一种神经节苷脂缓释片及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1199116B (it) * | 1984-07-03 | 1988-12-30 | Fidia Farmaceutici | Derivati di gangliosidi |
IT1208751B (it) * | 1986-06-30 | 1989-07-10 | Fidia Farmaceutici | Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali |
IT1235161B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisogangliosidi |
IT1249034B (it) * | 1990-06-29 | 1995-02-11 | Fidia Spa | Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi |
IT1253832B (it) * | 1991-08-01 | 1995-08-29 | Fidia Spa | Derivati di gangliosidi |
-
1992
- 1992-03-13 IT ITMI920591A patent/IT1254280B/it active
-
1993
- 1993-03-12 EP EP93906509A patent/EP0630250A1/en not_active Withdrawn
- 1993-03-12 JP JP5515350A patent/JP2872809B2/ja not_active Expired - Fee Related
- 1993-03-12 ES ES96116051T patent/ES2161953T3/es not_active Expired - Lifetime
- 1993-03-12 AT AT96116051T patent/ATE206053T1/de not_active IP Right Cessation
- 1993-03-12 WO PCT/EP1993/000571 patent/WO1993017691A2/en not_active Application Discontinuation
- 1993-03-12 EP EP96116051A patent/EP0770389B1/en not_active Expired - Lifetime
- 1993-03-12 DE DE69330842T patent/DE69330842T2/de not_active Expired - Lifetime
-
1994
- 1994-09-12 US US08/304,391 patent/US6620792B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69330842D1 (de) | 2001-10-31 |
ES2161953T3 (es) | 2001-12-16 |
WO1993017691A2 (en) | 1993-09-16 |
JP2872809B2 (ja) | 1999-03-24 |
ITMI920591A0 (it) | 1992-03-13 |
EP0630250A1 (en) | 1994-12-28 |
EP0770389B1 (en) | 2001-09-26 |
ATE206053T1 (de) | 2001-10-15 |
JPH07508258A (ja) | 1995-09-14 |
DE69330842T2 (de) | 2002-04-04 |
EP0770389A1 (en) | 1997-05-02 |
ITMI920591A1 (it) | 1993-09-13 |
WO1993017691A3 (en) | 1993-11-11 |
US6620792B1 (en) | 2003-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
NO920740D0 (no) | Doseringsform for oral administrering av hypoglykemisk glipizid | |
AU1358695A (en) | Nasal administration | |
EP1014996A4 (en) | SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS | |
NZ312715A (en) | Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues | |
HK1025915A1 (en) | Method of treating dry eye disease with purinergicreceptor agonist. | |
ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
IL99699A0 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
EP1020179A4 (en) | PEPTIDE DERIVATIVES OR THEIR PHARMACEUTICAL ACCEPTABLE SALTS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE DERIVATIVES AND MEDICINAL PRODUCTS | |
IT1254280B (it) | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson | |
DK160129C (da) | Farmaceutisk praeparat indeholdende en gangliosidforbindelse, et indre ester-gangliosidderivat eller blandinger deraf | |
CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
RU95105973A (ru) | Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза | |
CA2126118A1 (en) | 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative | |
WO1990014831A3 (en) | 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition | |
KR900012881A (ko) | 2,3,23-트리하이드록시-우르스-12-엔 및 이의 유도체 이의 제조방법 및 이의 용도 | |
FI104071B1 (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi | |
ATE69381T1 (de) | Anwendung exogener ganglioside zur herstellung eines arzneimittels zur anwendung bei tumorkrankheiten als schutzmittel gegen die toxizitaet tumorhemmender arzneimittel. | |
DE3175733D1 (en) | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | |
PH15640A (en) | A method for the treatment of pyrexia due to the accentuation of central nerve by administering a derivative of o-aminobenzoic acid | |
KR950008502A (ko) | 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제 | |
EP0180608B1 (en) | 2,3-diamino-2,3-didesoxyhexose derivatives, processes for their preparation and their use | |
CA2200516A1 (en) | Benzopyran derivative and method for treating heart disease using said benzopyran derivative | |
FR2387035A1 (fr) | Nouveau medicament destine notamment au traitement des troubles fonctionnels cerebraux | |
Devlin et al. | Intraocular Penetration of Topical Clindamycin in Rabbits: II. Clindamycin Phosphate |